High-Throughput Dried Blood Spot (HT-DBS) Technologies in SARS COV-2 Serology and Vaccinology

SARS COV-2 血清学和疫苗学中的高通量干血斑 (HT-DBS) 技术

基本信息

批准号：
10222023
负责人：
Nicholas J. Mantis
金额：
$ 115.32万
依托单位：
WADSWORTH CENTER
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-30 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10222023
关键词：
2019-nCoV Address Antibodies Antibody Response Antibody titer measurement Antigens Biological Assay Blood COVID-19 COVID-19 pandemic Clinical Communities Disease Outbreaks Employee Food Services General Population Goals HIV/HCV Health Health Personnel Hordeolum Human Immunity Immunoassay Immunoglobulin A Immunoglobulin G Immunoglobulin M Individual Infection Laboratories Liquid substance Measures Methodology Methods Microspheres Mission Modeling National Cancer Institute National Institute of Allergy and Infectious Disease New York Plasma Population Principal Investigator Proteins Saliva Sampling Schools Science Sensitivity and Specificity Serologic tests Serological Seroprevalences Serum Spottings Technology Testing Time United States Vaccines Virus Work base co-infection cohort first responder immunological status improved member minimally invasive neutralizing antibody neutralizing monoclonal antibodies nonhuman primate pre-clinical sample collection vaccine candidate vaccine trial vaccinology

项目摘要

Project Summary As the COVID-19 pandemic continues to spread across the United States it is imperative that we implement technologies to screen large swaths of the population for the presence of antibodies to SARS-CoV-2. Serological surveillance not only affords a measure of virus exposure within a community at large but also provides information necessary to predict outbreak dynamics. Furthermore, as our understanding of how humoral factors contribute to controlling (and possibly exacerbating) COVID-19, it will be essential to have methods in place to measure the “quantity” and “quality” of antibodies associated with both natural SARS-CoV- 2 exposure and candidate SARS-CoV-2 vaccines. This U01 proposal seeks to advance the use of dried blood spots (DBS) in conjunction with a Luminex-based microsphere immunoassay (MIA) to enable high-throughput (HT) population-wide serological surveillance for SARS-CoV-2. Specifically, the proposal will expand the HT- DBS assay to capture the breadth and complexity of SARS-CoV-2 antibody responses following natural infection, and develop a high-throughput competitive immunoassay (CIA) as a surrogate measure of SARS- CoV-2 neutralizing antibody titers in DBS. The proposed platform technologies to be developed at the Wadsworth Center will contribute directly to NCI’s mission to “… develop, validate, improve and implement serological testing and associated technologies…” to address the COVID-19 pandemic.

项目摘要随着19号大流行的遍及美国的流行，我们必须进行侵害用于筛选大量人群的技术，以实现SARS-COV-2的抗体。血清学监测不仅为整个社区中的病毒暴露提供了一种量度提供了预测爆发动态所需的信息。体液因素有助于控制（可能加剧）covid-19，至关重要测量与两种天然SARS-COV相关的抗体的“数量”和“质量”的方法 2暴露和候选SARS-COV-2疫苗。与基于Luminex的微球免疫测定（MIA）结合使用的斑点（DBS）以实现高通量（HT）SARS-COV-2的人口范围内的血清学监测。 DBS分析以捕获自然后SARS-COV-2抗体响应的宽度和压缩率感染，并发展高压竞争性免疫测定（CIA）作为SARS-的替代度量 COV-2中和DBS中的抗体滴度。沃兹沃思中心将促进NCI的使命：“……发展，验证，改进，改进和实施血清学测试和相关技术……“解决COVID-19的大流行。